Business
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows: Leerink Partners Global Healthcare ConferenceMarch 8 - 11, 2026 in Miami, FLFireside chat on March 9 at 9:20 AM ET InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the
About this update from Inflarx N.v.
[{"type":"image","alt":"InflaRx N.V.","displaySize":"","headline":null,"caption":"InflaRx N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lqiU0gFIS0tiIdhYPTjZSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/105c0226a90fc647941f68c2de55213a","width":300,"height":157}},"lazy":false},{"type":"text","content":"JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows:","length":297,"tagName":"p"},{"type":"text","content":"Leerink Partners Global Healthcare ConferenceMarch 8 - 11, 2026 in Miami, FLFireside chat on March 9 at 9:20 AM ET","length":116,"tagName":"p"},{"type":"text","content":"InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside chat live stream and its replay is available here.","length":147,"tagName":"p"},{"type":"text","content":"About InflaRxInflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa (HS). The Company has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.","length":1079,"tagName":"p"},{"type":"text","con...